{"id":"epoetin-hospira-arm","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"10-20","effect":"Headache"},{"rate":"1-5","effect":"Thrombotic events (DVT, PE, stroke)"},{"rate":"<1","effect":"Pure red cell aplasia"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL2109092","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Epoetin alfa is a biosynthetic form of human erythropoietin (EPO), a hormone that regulates red blood cell production. It binds to EPO receptors on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity in patients with anemia.","oneSentence":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:17.071Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients undergoing elective surgery"}]},"trialDetails":[{"nctId":"NCT02504294","phase":"PHASE3","title":"A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-07-13","conditions":"Chronic Kidney Disease (CKD)","enrollment":432},{"nctId":"NCT01170078","phase":"PHASE1","title":"A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2010-07","conditions":"Chronic Renal Failure","enrollment":107},{"nctId":"NCT01423955","phase":"PHASE2","title":"Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2011-10","conditions":"Kidney Failure, Renal Failure","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ESA","Erythropoetin Stimulating Agent","Erythropoetin Stimulation Agents"],"phase":"phase_3","status":"active","brandName":"Epoetin Hospira Arm","genericName":"Epoetin Hospira Arm","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing elective surgery.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}